A recently published article by Julie Hoover-Fong et al.1 seeks to synthesize the current knowledge base about the nature, incidence, chronology, and the interrelationships of achondroplasia-related comorbidities across the lifespan.

The Tsumaki lab, at the Center for iPS Cell Research and Application (CiRA), Kyoto University, is leading new research for achondroplasia with ASP5878, an FGFR inhibitor, using iPS cells. This is a study in collaboration with Astellas Pharma.

Among many rare skeletal disorders, achondroplasia is one of the best known and understood. Yet, its management and treatment are still a major challenge for research centers.

Pfizer released a Press Statement of the first children with achondroplasia receiving Recifercept, initiating the Phase 2 clinical trial

The Phase 2 Study Of Safety, Tolerability And Effectiveness Of Reciferecept In Children With Achondroplasia is now live in Clinicaltrial.gov

BioMarin shared an update on the 111-209: Phase 2 Study for Children at Risk of Requiring Cervicomedullary Decompression Surgery and the publication of Phase 3 clinical study.